Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Centro Interdipartimentale di Ricerche sul Cancro G. Prodi, Università di Bologna, Bologna, Italy.
Mol Cancer Res. 2016 Sep;14(9):820-9. doi: 10.1158/1541-7786.MCR-16-0068. Epub 2016 Jun 2.
Dermatofibrosarcoma protuberans (DFSP) is a rare and indolent cutaneous sarcoma. At times, a fibrosarcomatous transformation marked by a more aggressive clinical behavior may be present. We investigated the natural history and the molecular bases of progression from classic DFSP to the fibrosarcomatous form (FS-DFSP), looking, retrospectively, at the outcome of all patients affected by primary DFSP treated at our institution from 1993 to 2012 and analyzing the molecular profile of 5 DFSPs and 5 FS-DFSPs by an integrated genomics approach (whole transcriptome sequencing, copy number analysis, FISH, qRT-PCR, IHC). The presence of fibrosarcomatous features was identified in 20 (7.6%) patients out of 263 DFSP. All cases were treated with macroscopic complete surgery. A local relapse occurred in 4 of 23 patients who received a microscopic marginal surgery (2 classic DFSP, 2 FS-DFSP), while metastasis affected 2 patients, both FS-DFSP (10% of FS-DFSP), being the first event. DFSP evolution to FS-DFSP was paralleled by a transcriptional reprogramming. The recurrent loss of chromosome 22q appeared to contribute to this phenomenon by promoting the expression of epigenetic regulators, such as EZH2. Loss of the p16/CDKN2A/INK4A locus at 9p was also observed in two FS-DFSP metastatic cases.
FS-DFSP is a rare subgroup among DFSP, with a 10% metastatic risk, that was independent from local recurrence and that was not observed in DFSP, that were all cured by wide surgery. Chromosome 22q deletion might play a role in FS-DFSP, and p16 loss may convey a poor outcome. EZH2 dysregulation was also found and represents a druggable target. Mol Cancer Res; 14(9); 820-9. ©2016 AACR.
隆突性皮肤纤维肉瘤(DFSP)是一种罕见的、惰性的皮肤肉瘤。有时,纤维肉瘤样转化可能存在,其表现为更具侵袭性的临床行为。我们回顾性地研究了从经典 DFSP 到纤维肉瘤样形式(FS-DFSP)的自然病史和分子基础,研究了 1993 年至 2012 年在我们机构治疗的所有原发性 DFSP 患者的结局,并通过综合基因组学方法(全转录组测序、拷贝数分析、FISH、qRT-PCR、IHC)分析了 5 例 DFSP 和 5 例 FS-DFSP 的分子谱。在 263 例 DFSP 中,有 20 例(7.6%)患者存在纤维肉瘤样特征。所有病例均采用宏观完全手术治疗。23 例接受显微镜下边缘手术的患者中有 4 例(2 例经典 DFSP,2 例 FS-DFSP)局部复发,2 例转移,均为 FS-DFSP(FS-DFSP 的 10%)。DFSP 向 FS-DFSP 的进化伴随着转录重编程。染色体 22q 的反复缺失似乎通过促进表观遗传调节剂(如 EZH2)的表达促进了这一现象。在两个 FS-DFSP 转移病例中也观察到 9p 上的 p16/CDKN2A/INK4A 缺失。
FS-DFSP 是 DFSP 中的一个罕见亚组,转移风险为 10%,与局部复发无关,在广泛手术治愈的 DFSP 中未观察到。染色体 22q 缺失可能在 FS-DFSP 中起作用,p16 缺失可能预示不良预后。还发现了 EZH2 失调,这是一个可治疗的靶点。 Mol Cancer Res; 14(9); 820-9. ©2016 AACR.